An efficacy and safety report based on randomized controlled single-blinded multi-centre clinical trial of ZingiVir-H, a novel herbo-mineral formulation designed as an add-on therapy in adult patients with mild to moderate COVID-19.

Sasidharan, Shan; Nair J, Hareendran; K P, Srinivasakumar; Paul, Jerin; R, Madhu Kumar; Rajendran, Kannan; Saibannavar, Anita Ajit; Nirali, Sonali

Sasidharan, Shan; Nair J, Hareendran; K P, Srinivasakumar; Paul, Jerin; R, Madhu Kumar; Rajendran, Kannan; Saibannavar, Anita Ajit; Nirali, Sonali.

Afiliação

Sasidharan S; Department of Research and Development, Pankajakasthuri Herbal Research Foundation, Pankajakasthuri Ayurveda Medical College Campus, Thiruvananthapuram, Kerala, India.
Nair J H; Department of Research and Development, Pankajakasthuri Herbal Research Foundation, Pankajakasthuri Ayurveda Medical College Campus, Thiruvananthapuram, Kerala, India.
K P S; Institute of Biology and Clinical Research (IBCR), Thiruvananthapuram, Kerala, India.
Paul J; Department of Statistics, Vimala College (Autonomous), Thrissur, Kerala, India.
R MK; Mysore Medical College and Research Institute, Mysuru, Karnataka, India.
Rajendran K; Saveetha Medical College & Hospital, Chennai, India.
Saibannavar AA; RCSM Medical College & CPR Hospital, Dasara Chowk, Kolhapur District, Maharashtra, India.
Nirali S; Life Point Multi Specialty Hospital, Pune, Maharashtra, India.

PLoS One ; 17(12): e0276773, 2022.

Article em En | MEDLINE | ID: mdl-36472969

Assuntos

COVID-19; Humanos; Adulto; SARS-CoV-2; Tratamento Farmacológico da COVID-19; China; Índia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Humans País/Região como assunto: Asia Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Índia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google